Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of aspirin eugenol ester in preparation of drugs for preventing or treating Alzheimer's disease

A technology for Alzheimer's disease and eugenol ester, applied in the field of medicine, can solve the problems of difficult to obtain satisfactory therapeutic effect, unsatisfactory long-term therapeutic effect, poor patient compliance, etc., so as to achieve the prevention or treatment of Alzheimer's disease. Significant and anti-apoptotic effect

Active Publication Date: 2021-07-02
LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide an application of aspirin eugenol ester in the preparation of drugs for the prevention or treatment of Alzheimer's disease, aiming to solve the problem that the existing small molecule drugs for AD treatment are only suitable for mild to moderate patients to improve cognitive function , the long-term treatment effect is not ideal, it cannot reverse or prevent the progression of AD, and it is expensive, resulting in poor patient compliance, and it is difficult to achieve satisfactory treatment effects through a single target or pathway

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of aspirin eugenol ester in preparation of drugs for preventing or treating Alzheimer's disease
  • Application of aspirin eugenol ester in preparation of drugs for preventing or treating Alzheimer's disease
  • Application of aspirin eugenol ester in preparation of drugs for preventing or treating Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Transcriptomics experiment based on heart tissue

[0023] Twenty healthy male Wistar rats of SPF grade at the age of 8-10 weeks, weighing 200±20g, were randomly divided into 2 groups, 10 rats in each group. They were blank control group (0.5% CMC-Na) and AEE group (36mg / kg). The corresponding drugs were given to the animals in the two groups by intragastric administration, once a day, for 7 consecutive days. On the 8th day, heart tissue was collected, total RNA was extracted, and 7 samples were randomly selected from each group as mixed samples for gene expression profiling chip detection.

[0024] GO cluster analysis of gene expression profile chip data, screening all GO Term with P≤0.05, the analysis results are as follows figure 1 shown.

[0025] figure 1 A is the enrichment percentage of differential genes in the biological process. Compared with the blank control group, the G protein-coupled receptor protein signaling pathway (26.9%), cell adhesion (9...

Embodiment 2

[0031] Example 2 Transcriptomics experiment based on brain tissue

[0032] Twenty healthy male Wistar rats of SPF grade at the age of 8-10 weeks, weighing 200±20g, were randomly divided into 2 groups, 10 rats in each group. They were blank control group (0.5% CMC-Na) and AEE group (72mg / kg). The corresponding drugs were given to the animals in the two groups by intragastric administration, once a day, for 7 consecutive days. On the 8th day, brain tissue was collected, total RNA was extracted, and 7 samples were randomly selected from each group as a mixed sample for gene expression profiling chip detection.

[0033] Statistical analysis of differentially expressed genes was screened with the absolute value of Fold change ≥ 2.0. The results are shown in Table 1.

[0034] Table 1 Statistical analysis of differentially expressed genes between AEE group and blank control group

[0035]

[0036] It can be seen from Table 1 that compared with the blank control group, the expre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of aspirin eugenol ester in the preparation of medicines for preventing or treating Alzheimer's disease. The effective dosage of aspirin eugenol ester in the medicine is 36-72mg / kg. Experimental results show that aspirin eugenol ester can Significantly change the expression of key genes in the Alzheimer's disease signaling pathway, affecting the occurrence and development of neurodegenerative diseases such as Alzheimer's disease. It can also inhibit cell apoptosis, reduce the inflammatory response in the brain and inhibit the expression of acetylcholinesterase. Play the role of preventing or treating Alzheimer's disease; the present invention uses aspirin eugenol ester to exert multi-target or multi-pathway effects to achieve the effect of preventing or treating Alzheimer's disease.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to a new application of aspirin eugenol ester, in particular to the application of aspirin eugenol ester in the preparation of drugs for preventing or treating Alzheimer's disease. Background technique [0002] Alzheimer's Disease (AD), commonly known as senile dementia, is currently the most serious central nervous system degenerative disease related to body aging. According to reports, with the acceleration of the aging process of my country's social population, its incidence rate is increasing year by year, and it has become the fourth disease that seriously threatens the health of the elderly after heart disease, tumor and stroke. An extremely heavy burden. Therefore, how to achieve the intervention of AD pathogenesis through effective means is an important health and social problem currently facing. [0003] The main lesions of AD are characterized by the extracellular depositio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/621A61P25/28
CPCA61K31/621A61P25/28
Inventor 李剑勇秦哲杨亚军刘希望焦增华李世宏孔晓军
Owner LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS